A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.

Exclusion Criteria

• •1. Other nasal comorbidities or co-morbidities/states that may be present at the time of screening that affect efficacy determination.
• •2. Subjects whose allergen exposures in their home or work environments may be expected to change significantly during the trial period.
• •3. Subjects with poorly controlled recent asthma conditions.
• •4. Presence of current or past history of infection of special concern, e.g., active tuberculosis, helminthic infections, severe herpes virus infections, etc.
• •5. Previous use of anti-interleukin 4 receptor alpha subunit (IL4Rα) monoclonal antibody.
• •6. Have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.